Strong Performance By Hungary's Egis In 1996

17 March 1997

Hungarian pharmaceutical company Egis achieved gross and net profits of5.58 billion forint ($31.7 million) in 1996, up 14% on the previous year. Operating profits totaled 4.97 billion forint, an increase of 23.2%, reports MTI Econews.

Sales in 1996 amounted to 24.69 billion forint, up 24.6%, and exports grew 25% to just over 11 billion forint. Turnover of packaged medicines last year was 20 billion forint, accounting for 82.3% of total sales, while turnover of active ingredients was 3.9 billion forint, or 16% of total sales. Revenues from nutritional supplements accounted for 1% of the total.

Of the packaged (ie finished) medicines turnover, cardiovascular drugs represented 48.5%, and respiratory products accounted for 14% of the total.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight